Table 3. Clinical characteristics of patients with or without brain metastases (BMs).
| Characteristic | Patients with BMs (n = 42) | Patients without BMs (n = 98) | P-value |
|---|---|---|---|
| Age (years), n (%) | 0.970 | ||
| < 65 | 26 (61.9) | 61 (62.2) | |
| ≥ 65 | 16 (38.1) | 37 (37.8) | |
| Sex, n (%) | 0.732 | ||
| M | 15 (35.7) | 38 (38.8) | |
| F | 27 (64.3) | 60 (61.2) | |
| BMI, n (%)a | 0.405 | ||
| < 20 | 4 (9.5) | 14 (14.3) | |
| ≥ 20 | 38 (90.5) | 84 (85.7) | |
| Weight loss at diagnosis, n (%) | 0.756 | ||
| ≤ 10.0% | 32 (76.2) | 77 (78.6) | |
| > 10.0%b | 10 (23.8) | 21 (21.4) | |
| ECOG PS, n (%) | 0.003* | ||
| 0–1 | 34 (81.0) | 95 (96.9) | |
| 2–4 | 8 (19.0) | 3 (3.1) | |
| EGFR mutation status, n (%) | 0.921 | ||
| Group 1c | 33 (78.5) | 75 (76.5) | |
| Group 2d | 2 (4.8) | 4 (4.1) | |
| Group 3e | 7 (16.7) | 19 (19.4) | |
| Weight loss of >5.0% during afatinib treatment, n (%) | 25 (59.5) | 41 (41.8) | 0.066 |
| PD event, n (%) | 34 (81.0) | 43 (43.9) | < 0.001* |
| PD due to brain event, n (%) | 16 (38.1) | 10 (10.2) | 0.023* |
* P < 0.05
aBMI = body weight (kg)/body height (m)2
bSignificant weight loss of > 10.0% within 6 months of diagnosis
cClassical mutation(s)
dComplex mutation with classical mutation
eRare mutation with or without complex mutation
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; F, female; M, male; PD, progressive disease; PS, performance status